📈 Jumpstart Signal Watchlist — November 10, 2026

🏢 What they do: DiamondRock Hospitality Company (DRH) is a self-advised real estate investment trust (REIT) that owns a portfolio of approximately 35-36 premium hotels and resorts with about 9,600 rooms, concentrated in U.S. gateway markets and leisure destinations.
- 🎯 At/above 3yr high $14.70 (current $14.70) · ⏳ SMA200 $11.45 (current price $14.70 is above) · 💰 Market Cap $3.0B
- DRH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 52/60
- 🏦 Low drawdown (10.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 60% (>20%); Low LT D/E 0.71 (<1.0); PEG ratio 0.31 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.4%)
- 🔔 Strong above EMA50 (10.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ What DiamondRock Hospitality (DRH) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 DiamondRock raised its 2026 outlook after reporting year-over-year growth in RevPAR and hotel adjusted EBITDA. The article also notes stronger-than-expected October results and the acquisition of The Bellmoor Inn & Spa.
✅ DIAMONDROCK HOSPITALITY COMPANY REPORTS THIRD QUARTER 2026 RESULTS — PR Newswire.
🤖 Third-quarter net income and comparable hotel adjusted EBITDA increased year over year, and the company raised its quarterly dividend by 22%. The release also reports the acquisition of The Bellmoor Inn & Spa.
⚪️ DiamondRock Hospitality (DRH) Q3 FFO Meet Estimates — Yahoo Finance.
🤖 Quarterly FFO of $0.32 per share matched consensus and was above the year-ago figure. Revenue increased year over year but missed the cited consensus estimate slightly, making the report mixed.
⚪️ DiamondRock Hospitality: Q3 Earnings Snapshot — Yahoo Finance (Associated Press).
🤖 FFO per share matched analysts’ expectations, while reported revenue fell short of the cited Street forecast. The company’s full-year FFO outlook was $1.24 to $1.26 per share.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Sunstone Hotel Investors, Inc. is a lodging real estate investment trust (REIT) that acquires, actively owns, and disposes of well-located hotel and resort real estate to create long-term stakeholder value. The company owns a geographically diverse portfolio of 15 upper upscale and luxury hotels, the majority of which are operated under nationally recognized brands.
- 🎯 Current $12.78 is 2% below 3yr high $13.01 · ⏳ SMA200 $10.65 (current price $12.78 is above) · 💰 Market Cap $2.3B
- SHO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 52/60
- 🏦 Low drawdown (10.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1150% (>20%); Low LT D/E 0.53 (<1.0); PEG ratio 0.02 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ Sunstone Raises 2026 Outlook as Q3 RevPAR Climbs 11.4% — Yahoo Finance.
🤖 Sunstone reported higher third-quarter RevPAR and net income, then raised its 2026 adjusted FFO and RevPAR outlook. The stronger results and improved guidance are positive signals for the stock.
✅ Sunstone Hotel: Q3 Earnings Snapshot — Associated Press.
🤖 Sunstone's third-quarter FFO per share exceeded analysts' expectations, and the company reported net income compared with a loss a year earlier. The results and higher full-year FFO outlook are favorable for the stock.
❌ Evercore ISI Group Downgrades Sunstone Hotel Invts to In-Line, Maintains Price Target to $13 - Sunstone H — Benzinga.
🤖 Evercore ISI downgraded Sunstone to In-Line while keeping its $13 price target unchanged. The downgrade is a negative analyst signal, though the maintained target limits the change in outlook.
🍭 Bonus (B): 0/10 — Hotels & Motels

🏢 What they do: ACCO Brands designs, manufactures, and markets branded office, school, and consumer products. Its offerings include notebooks and planners, filing and organization supplies, office equipment, computer accessories, and gaming products.
- 🎯 Current $5.35 is 19% below 3yr high $6.59 · ⏳ SMA200 $4.00 (current price $5.35 is above) · 💰 Market Cap $494M
- ACCO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.9%)
- 🔔 Strong above EMA50 (15.6%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×3 ❌×1 ⚪️×1; showing 4 of 5).
✅ Wall Street Analysts Predict a 46.52% Upside in Acco (ACCO): Here's What You Should Know — Zacks.
🤖 The article cites an average analyst price target of $8 versus the recent share price of $5.46 and a Zacks Rank of Strong Buy. It presents analyst expectations as indicating potential upside, though price targets are estimates rather than guarantees.
✅ ACCO Brands Reports Third Quarter Results — Seeking Alpha.
🤖 ACCO reported adjusted EPS of $0.28, above the $0.19 consensus, and raised its full-year outlook to reflect tariff refunds and the Trust acquisition. Sales were slightly lower year over year and in line with the company’s outlook.
❌ Acco Brands (NYSE:ACCO) Stock Rating Cut to "Buy" at Wall Street Zen — MarketBeat.
🤖 Wall Street Zen downgraded ACCO from Strong Buy to Buy, a modestly negative analyst-rating change. The article also notes that quarterly EPS beat estimates while revenue came in slightly below them.
⚪️ ACCO Brands declares $0.075 quarterly dividend per share — Investing.com.
🤖 The company declared a quarterly dividend of $0.075 per share. This routine dividend announcement provides income to shareholders but does not, by itself, indicate a change in the company’s outlook.
🍭 Bonus (B): 0/10 — Printing & Publishing

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $70.58 is 3% below 3yr high $72.75 · ⏳ SMA200 $51.71 (current price $70.58 is above) · 💰 Market Cap $17.3B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 23% (>20%); ROE 48% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.5%)
- 🔔 Strong above EMA50 (12.5%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Exelixis at guggenheim healthcare innovation conference — Investing.com.
🤖 Management described continued share gains for the CABO franchise and positioned zanzalintinib as a potential future growth engine. The outlook was upbeat, though the article also noted clinical-development and competitive risks.
✅ Exelixis (NASDAQ:EXEL) Upgraded at Wall Street Zen — MarketBeat.
🤖 Wall Street Zen upgraded Exelixis to Strong Buy, and the article also reported higher price targets from several analysts. It cited third-quarter earnings and revenue that exceeded expectations.
⚪️ Exelixis beats Q3 estimates but stock edges lower on guidance — Investing.com.
🤖 Exelixis beat third-quarter earnings and revenue estimates, with revenue up 10.2% year over year. However, it maintained full-year revenue guidance whose midpoint was slightly below analyst consensus, and shares edged lower.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $80.77 is 9% below 3yr high $88.47 · ⏳ SMA200 $35.80 (current price $80.77 is above) · 💰 Market Cap $4.2B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (13.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1067% (>20%); Revenue growth 39% (>15%); ROE 28% (>15%).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (7.2%)
- 🔔 Strong above EMA50 (22.2%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (59) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth — Zacks.
🤖 CareDx raised its 2026 revenue and adjusted EBITDA outlook after strong transplant testing demand and improved reimbursement collections. The article also reports 21% year-over-year growth in transplant testing volumes.
✅ Favorable Medicare Coverage Ruling Drives CareDx’s (CDNA) Q3 Performance — Yahoo Finance.
🤖 The article describes a favorable CMS reimbursement outcome for CareDx’s kidney, heart, and lung transplant tests and its contribution to strong quarterly share performance. Improved coverage and reimbursement support the company’s business outlook.
⚪️ CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Yahoo Finance.
🤖 CareDx granted restricted stock units to 21 new employees as an inducement to join the company. This routine compensation disclosure does not report a material operating or financial catalyst.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Zeta Global is an AI-powered marketing technology company that provides enterprises with a unified platform combining identity data, artificial intelligence, and multichannel marketing tools to acquire, grow, and retain customers.
- 🎯 Current $35.07 is 4% below 3yr high $36.74 · ⏳ SMA200 $22.87 (current price $35.07 is above) · 💰 Market Cap $8.6B
- ZETA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 800% (>20%); Revenue growth 46% (>15%); Low LT D/E 0.24 (<1.0); PEG ratio 0.29 (<1.5).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (8.7%)
- 🔔 Strong above EMA50 (12.5%)
- 🔔 Fresh SMA50 breakout
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Zeta Global Stock Surges on Positive Q3 Results — Benzinga.
🤖 Zeta beat analyst estimates for third-quarter earnings and revenue, then issued fourth-quarter and full-year sales guidance above expectations. The article also reported that shares were rising following the results.
✅ ZETA Q3 Earnings Call Highlights AI Growth and Higher Outlook — Yahoo Finance.
🤖 The earnings-call recap reports strong revenue and adjusted earnings growth, alongside higher full-year revenue, EBITDA, and free-cash-flow guidance. Management also described growing AI adoption and enterprise opportunities.
✅ Zeta Global Holdings (ZETA) Tops Q3 Earnings and Revenue Estimates — Yahoo Finance.
🤖 Zeta reported adjusted earnings per share and revenue above consensus estimates for the quarter. The earnings surprise and year-over-year revenue growth are favorable signals for the stock.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: LTC Properties, Inc. is a real estate investment trust (REIT) focused on senior housing and healthcare properties in the United States. It invests in and leases properties such as skilled nursing facilities, assisted living communities, and memory care facilities to healthcare operators.
- 🎯 Current $44.47 is 4% below 3yr high $46.33 · ⏳ SMA200 $39.79 (current price $44.47 is above) · 💰 Market Cap $2.4B
- LTC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (11.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1552% (>20%); Revenue growth 66% (>15%); ROE 31% (>15%).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ RBC Lifts Price Target on LTC Properties to $53 From $52, Keeps Outperform Rating — Yahoo Finance.
🤖 RBC raised its price target while maintaining its Outperform rating, signaling a more favorable valuation outlook for LTC Properties.
✅ LTC Properties Q3 2026 slides: $1B SHOP pivot reshapes portfolio — Investing.com.
🤖 The article reports quarterly results above expectations and substantial SHOP acquisitions, supporting the company’s portfolio transformation. The rapid expansion is a potential growth driver, though it also reflects a significant strategic shift.
⚪️ What LTC Properties (LTC) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 Management reported nearly $950 million in SHOP acquisitions through October and maintained full-year core FFO guidance. However, it trimmed the midpoint of 2026 core SHOP NOI guidance, tempering the positive growth outlook.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Porch Group provides homeowners insurance and software for home-related businesses such as inspectors, mortgage providers, and title companies. It also offers consumer services including moving assistance, home warranties, and help arranging home setup and maintenance services.
- 🎯 At/above 3yr high $21.95 (current $21.95) · ⏳ SMA200 $12.45 (current price $21.95 is above) · 💰 Market Cap $2.7B
- PRCH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 46/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); Revenue growth 22% (>15%); ROE 127% (>15%); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (13.4%)
- 🔔 Strong above EMA50 (22.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×2).
✅ Porch Group Reports Third Quarter 2026 Results — Yahoo Finance.
🤖 Porch said its third-quarter results exceeded expectations. The results announcement is a positive company-specific catalyst, though the search snippet does not provide further financial details.
✅ Porch Group Q3 2026 slides: 42% policy growth, EBITDA doubles — Investing.com.
🤖 The article reports 42% year-over-year growth in reciprocal policies written and more than doubled adjusted EBITDA. It also says Porch raised its full-year guidance for the third consecutive quarter, supporting a positive assessment.
⚪️ Porch Group CEO Matt Ehrlichman sells $2.2M in common stock — Investing.com.
🤖 The CEO sold shares under a Rule 10b5-1 trading plan adopted in 2025. This is a reported insider transaction, but the article does not establish it as a new directional catalyst.
⚪️ Porch Group Announces Attendance at Upcoming Investor Events — Business Wire.
🤖 The company announced management’s participation in upcoming investor meetings and conferences. The notice reports no new financial results, guidance, or other material catalyst.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)